Investors should give European stockmarkets a second look
Investors tend to think that European stockmarkets are full of stale “old economy” firms while the US is full of fast-growing tech stocks. But European markets now offer their own healthy mix of quality growth stocks.

A surge in coronavirus cases in Europe means that talk of a swift recovery is now a “summer memory”, says Peter Goodman in The New York Times. French prime minister Jean Castex this week acknowledged that “the second wave is here”, as governments across the continent tightened restrictions. Spain has declared a state of emergency in Madrid and instituted a partial lockdown there.
Economic gloom is spreading. France now expects activity to remain stuck at 95% of pre-pandemic levels for the rest of the year. Spanish business sentiment hit a four-month low last month. The pan-European Europe Stoxx 600 index is down 11% so far this year.
The changing of the guard
The common investment “trope” is that Europe is full of “old economy” firms while the US races ahead with technology, says Graham Secker in the Financial Times. Yet that idea is “outdated”. Banks and energy no longer dominate the MSCI Europe index. Indeed, the weighting of banks on European indices is now the same as the global average. The areas where European markets are “overweight” the global average today – healthcare, consumer staples and industrials – offer a “healthy mix of good, quality growth”. The European “leopard is indeed changing its spots”.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
If the US market is increasingly a wager on tech, then Europe is “a bet on drugs”, says Stephen Wilmot in The Wall Street Journal. Five of its ten biggest firms are now drugs firms. Back in 2004 the top three Stoxx Europe 50 firms were all British: BP, HSBC and Vodafone. Today’s leading trio are Swiss: two pharmaceutical giants (Roche and Novartis) and Nestlé. Europe offers other “growth niches” as well, from French luxury goods to Danish cleantech (energy efficiency), says Reshma Kapadia in Barron’s. America’s S&P 500 has “eviscerated” other markets over the past decade, “returning 13.9% a year, on average” against 5.5% for the World ex-US.
Yet stretched valuations are giving Americans the “urge to do some portfolio globe-trotting”. If we strip out expectations about growth and just look at current valuations, then US equities are “priced to deliver” just 0.5% in annual real returns over the next decade, says Robert Arnott, the founder of Research Affiliates. Europe and Japan are offering real returns of “about 5%”.
A German anchor
Germany’s Dax has outperformed other European markets this year, falling by just 2.2%, thanks to the country’s export-led exposure to the strong Chinese recovery, says Anna Isaac in The Wall Street Journal. Analysts think German carmakers will also get a boost as the pandemic makes more people avoid public transport. In 2018 the debt of German non-financial companies was about 58% of GDP, compared with 84% in the UK and 141% in France. As Christoph Ohme of DWS Group puts it, strong public and corporate finances make Germany resilient in a crisis. It is a “stable anchor” for the world economy.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Alex is an investment writer who has been contributing to MoneyWeek since 2015. He has been the magazine’s markets editor since 2019.
Alex has a passion for demystifying the often arcane world of finance for a general readership. While financial media tends to focus compulsively on the latest trend, the best opportunities can lie forgotten elsewhere.
He is especially interested in European equities – where his fluent French helps him to cover the continent’s largest bourse – and emerging markets, where his experience living in Beijing, and conversational Chinese, prove useful.
Hailing from Leeds, he studied Philosophy, Politics and Economics at the University of Oxford. He also holds a Master of Public Health from the University of Manchester.
-
Billions of pounds languishing in low interest accounts as savings rates slashed
Savers are being urged to act as billions of pounds earn paltry interest rates. It comes as interest rates on variable savings accounts have fallen to their lowest levels since 2023.
By Daniel Hilton Published
-
Review: Cali, Mykonos – salute the sun in Greece
Chris Carter engages in a sunset ritual of his own at Cali on the Greek island of Mykonos
By Chris Carter Published
-
The benefits of a stock bubble
Opinion We tend to think of stock bubbles as bad things but, as the dotcom craze shows, good things can come from them, says Matthew Lynn
By Matthew Lynn Published
-
Why CEOs deserve a pay rise
Opinion The CEOs of big companies often come under fire for being grossly overpaid. But the truth, as per some economists, is the opposite. Do they merit a pay rise?
By Stuart Watkins Published
-
Rolls-Royce stock jumps 15% – could it climb further?
Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge
By Dr Matthew Partridge Published
-
The power of private markets
Interview Helen Steers, co-manager of the Pantheon International investment trust, tells MoneyWeek about the vast array of compelling opportunities in private equity
By Andrew Van Sickle Published
-
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success
By Dr Mike Tubbs Published
-
Global investors have overlooked these top tips in emerging markets
Opinion Chris Tennant, co-portfolio manager of Fidelity Emerging Markets, picks three attractive companies in emerging markets
By Chris Tennant Published
-
King Coal has not been dethroned yet — should you buy?
The demand for coal is only growing, yet investors don’t seem to want to take advantage of the opportunity, says Rupert Hargreaves
By Rupert Hargreaves Published
-
It’s time to start buying Europe again, says Merryn Somerset Webb
Opinion Europe's stocks are cheap and the economic backdrop is starting to look cheerier, says Merryn Somerset Webb
By Merryn Somerset Webb Published